Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLKS7W)

Drug Name

NV-5138 Drug Info

Synonyms

UNII-06CA9QMG6Z; 4-(difluoromethyl)-L-leucine; 2095886-80-7; SCHEMBL18762589; ZINC585143195; HY-114384; N[C@H](C(=O)O)CC(C(F)F)(C)C; CS-0084893; ((S)-2-Amino-5,5-difluoro-4,4-dimethylpentanoic acid; Pentanoic acid, 2-amino-5,5-difluoro-4,4-dimethyl-, (2S)-; K94

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Phase 1	[1]

Cross-matching ID

PubChem CID: 129050791
CAS Number: CAS 2095886-80-7
TTD Drug ID: DMLKS7W

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mammalian target of rapamycin complex 1 (mTORC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RBT-101	DMDZW8K	Respiratory tract infection	CA45	Phase 3	[3]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
ME-344	DM6JN19	Breast cancer	2C60-2C65	Phase 1/2	[4]
VS-5584	DMMO3G5	Malignant mesothelioma	2C26.0	Phase 1	[5]
Palomid-529	DM428Y3	Alzheimer disease	8A20	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mammalian target of rapamycin complex 1 (mTORC1)	TTX4GLS	MTOR_HUMAN-RPTOR_HUMAN-LST8_HUMAN-AKTS1_HUMAN-DPTOR_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03606395) Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression. U.S. National Institutes of Health.
2	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554.
3	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.